Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Lennon
LENDITRO TABLETS SCHEDULING STATUS: S3 PROPRIETARY NAME: (and dosage form) LENDITRO TABLETS COMPOSITION: Each tablet contains: Oxybutynin chloride 5 mg. PHARMACOLOGICAL CLASSIFICATION: A - 5.4: Medicines affecting autonomic functions. Cholinolytics (Anticholinergics). PHARMACOLOGICAL ACTION: LENDITRO tablets exert a direct antispasmodic effect on smooth muscle. Oxybutynin chloride inhibits the muscarinic action of acetylcholine on smooth muscle. In patients with uninhibited neurogenic and reflex neurogenic bladder, cystometric studies have demonstrated that oxybutynin chloride increases vesical capacity, diminishes the frequency of uninhibited contractions of the detrusor muscle and delays the initial desire to void. These effects are more consistently improved in patients with uninhibited neurogenic bladder. INDICATIONS: LENDITRO tablets are indicated for the relief of symptoms associated with voiding in patients with uninhibited neurogenic and reflex neurogenic bladder, (i.e. urgency, frequency, urinary leakage, urge incontinence, dysuria). LENDITRO tablets are indicated for spastic neurogenic bladder (and not hypotonic neurogenic bladder - see Contra- indications). LENDITRO is indicated for nocturnal enuresis. CONTRA-INDICATIONS: LENDITRO tablets are contra-indicated in patients with closed-angle glaucoma. They are also contra-indicated in patients with prostatic enlargement and should be used with caution in elderly men. LENDITRO tablets are contra-indicated in partial or complete obstruction of the gastro-intestinal tract, paralytic ileus, intestinal atony of the elderly or debilitated patient, megacolon, toxic megacolon complicating ulcerative colitis, severe colitis and myasthenia gravis. They are also contra-indicated in patients with obstructive uropathy and in patients with unstable cardio-vascular statu Read the complete document